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Errata
Emergency admission for cancer - a matter of
survival?
In the article entitled 'Emergency admission for cancer - a matter
ofsurvival?,' which appeared in BrJ Cancer 77: 353-358, the
ratios ofthe number ofpatients who died/number ofpatients at
risk in the emergency admission group in Figure 1 are inverted.
This should be corrected as follows:
'T = 10 months: 86/72, T = 30 months: 114/36, T = 50 months,
121/22.'
We apologize for the typographical error that occurred in the orig-
inal publication.
MPorta, EFernandez, JBelloc, NMalats, M Gallen and
JAlonso
Phase 1 study on docetaxel and ifosfamide in patients
with advanced solid tumours
In the article entitled 'Phase I study on docetaxel and ifosfamide
in patients with advanced solid tumours, which appeared in BrJ
Cancer 77: 153-158, the discussion section on page 157
regarding administration ofifosfamide should be corrected as
follows:
,...active when administered intravenously...'
We apologise for the error that occurred in the original
publication.
LCPronk, D Schrijvers, JHMSchellens, EA de Bruijn,
ASTh Planting, D Locci-Tonelli, VGroult, J Verweij and
ATvan Oosterom
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